221 related articles for article (PubMed ID: 29119354)
21. Enrollment of racial/ethnic minorities in NIAID-funded networks of HIV vaccine trials in the United States, 1988 to 2002.
Djomand G; Katzman J; di Tommaso D; Hudgens MG; Counts GW; Koblin BA; Sullivan PS
Public Health Rep; 2005; 120(5):543-8. PubMed ID: 16224987
[TBL] [Abstract][Full Text] [Related]
22. Enrollment of adolescent and young adult patients newly diagnosed with cancer in NCI CTEP-sponsored clinical trials before and after launch of the NCI National Clinical Trials Network.
Sankaran H; Finnigan SR; McShane LM; Best AF; Seibel NL
Cancer; 2022 Nov; 128(21):3843-3849. PubMed ID: 36089859
[TBL] [Abstract][Full Text] [Related]
23. Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials.
London WB; Bagatell R; Weigel BJ; Fox E; Guo D; Van Ryn C; Naranjo A; Park JR
Cancer; 2017 Dec; 123(24):4914-4923. PubMed ID: 28885700
[TBL] [Abstract][Full Text] [Related]
24. Platinum salts in advanced breast cancer: a systematic review and meta-analysis of randomized clinical trials.
Petrelli F; Barni S; Bregni G; de Braud F; Di Cosimo S
Breast Cancer Res Treat; 2016 Dec; 160(3):425-437. PubMed ID: 27770282
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study.
Iizumi S; Shimoi T; Tsushita N; Bun S; Shimomura A; Noguchi E; Kodaira M; Yunokawa M; Yonemori K; Shimizu C; Fujiwara Y; Tamura K
BMC Cancer; 2017 Dec; 17(1):819. PubMed ID: 29202787
[TBL] [Abstract][Full Text] [Related]
26. Risks and benefits of phase 1 oncology trials, 1991 through 2002.
Horstmann E; McCabe MS; Grochow L; Yamamoto S; Rubinstein L; Budd T; Shoemaker D; Emanuel EJ; Grady C
N Engl J Med; 2005 Mar; 352(9):895-904. PubMed ID: 15745980
[TBL] [Abstract][Full Text] [Related]
27. Cancer trial enrollment after state-mandated reimbursement.
Gross CP; Murthy V; Li Y; Kaluzny AD; Krumholz HM
J Natl Cancer Inst; 2004 Jul; 96(14):1063-9. PubMed ID: 15265967
[TBL] [Abstract][Full Text] [Related]
28. A sense of urgency: Evaluating the link between clinical trial development time and the accrual performance of cancer therapy evaluation program (NCI-CTEP) sponsored studies.
Cheng SK; Dietrich MS; Dilts DM
Clin Cancer Res; 2010 Nov; 16(22):5557-63. PubMed ID: 21062929
[TBL] [Abstract][Full Text] [Related]
29. Recent innovations in the USA National Cancer Institute-sponsored investigator initiated Phase I and II anticancer drug development.
Bando H; Takebe N
Jpn J Clin Oncol; 2015 Nov; 45(11):1001-6. PubMed ID: 26423340
[TBL] [Abstract][Full Text] [Related]
30. Challenges Facing Early Phase Trials Sponsored by the National Cancer Institute: An Analysis of Corrective Action Plans to Improve Accrual.
Massett HA; Mishkin G; Rubinstein L; Ivy SP; Denicoff A; Godwin E; DiPiazza K; Bolognese J; Zwiebel JA; Abrams JS
Clin Cancer Res; 2016 Nov; 22(22):5408-5416. PubMed ID: 27401246
[TBL] [Abstract][Full Text] [Related]
31. Trends in Grade 5 Toxicity and Response in Phase I Trials in Hematologic Malignancy: 20-Year Experience From the Cancer Therapy Evaluation Program at the National Cancer Institute.
Chihara D; Huang EP; Finnigan SR; Cordes LM; Skorupan N; Fukuda Y; Rubinstein LV; Ivy SP; Doroshow JH; Nastoupil LJ; Flowers CR; Takebe N
J Clin Oncol; 2022 Jun; 40(17):1949-1957. PubMed ID: 35263120
[TBL] [Abstract][Full Text] [Related]
32. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
[TBL] [Abstract][Full Text] [Related]
33. Towards using a full spectrum of early clinical trial data: a retrospective analysis to compare potential longitudinal categorical models for molecular targeted therapies in oncology.
Colin P; Micallef S; Delattre M; Mancini P; Parent E
Stat Med; 2015 Sep; 34(22):2999-3016. PubMed ID: 26059319
[TBL] [Abstract][Full Text] [Related]
34. Analysis of Maryland cancer patient participation in national cancer institute-supported cancer treatment clinical trials.
Baquet CR; Ellison GL; Mishra SI
J Clin Oncol; 2008 Jul; 26(20):3380-6. PubMed ID: 18612153
[TBL] [Abstract][Full Text] [Related]
35. Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends.
Moreno-Aspitia A; Perez EA
Clin Ther; 2009 Aug; 31(8):1619-40. PubMed ID: 19808124
[TBL] [Abstract][Full Text] [Related]
36. Phase I trial outcomes in older patients with advanced solid tumours.
Khan KH; Yap TA; Ring A; Molife LR; Bodla S; Thomas K; Zivi A; Smith A; Judson I; Banerji U; de Bono JS; Kaye SB
Br J Cancer; 2016 Feb; 114(3):262-8. PubMed ID: 26757260
[TBL] [Abstract][Full Text] [Related]
37. Gender minorities in breast cancer - Clinical trials enrollment disparities: Focus on male, transgender and gender diverse patients.
Miglietta F; Pontolillo L; De Angelis C; Caputo R; Marino M; Bria E; Di Rienzo R; Verrazzo A; Buonerba C; Tortora G; Di Lorenzo G; Del Mastro L; Giuliano M; Montemurro F; Puglisi F; Guarneri V; De Laurentiis M; Scafuri L; Arpino G
Breast; 2024 Jun; 75():103713. PubMed ID: 38493590
[TBL] [Abstract][Full Text] [Related]
38. Radiation-Therapeutic Agent Clinical Trials: Leveraging Advantages of a National Cancer Institute Programmatic Collaboration.
Takebe N; Ahmed MM; Vikram B; Bernhard EJ; Zwiebel J; Norman Coleman C; Kunos CA
Semin Radiat Oncol; 2016 Oct; 26(4):271-80. PubMed ID: 27619249
[TBL] [Abstract][Full Text] [Related]
39. Phase II trial of N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine.HCl and doxorubicin chemotherapy in metastatic breast cancer: A National Cancer Institute of Canada clinical trials group study.
Khoo K; Brandes L; Reyno L; Arnold A; Dent S; Vandenberg T; Lebwohl D; Fisher B; Eisenhauer E
J Clin Oncol; 1999 Nov; 17(11):3431-7. PubMed ID: 10550138
[TBL] [Abstract][Full Text] [Related]
40. A Systematic Review of Pediatric Phase I Trials in Oncology: Toxicity and Outcomes in the Era of Targeted Therapies.
Cohen JW; Akshintala S; Kane E; Gnanapragasam H; Widemann BC; Steinberg SM; Shah NN
Oncologist; 2020 Jun; 25(6):532-540. PubMed ID: 31943534
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
